GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions.
GM1 gangliosidosis is a rare lysosomal storage disorder characterized biochemically by deficient beta-galactosidase activity and clinically by a wide range of variable neurovisceral, ophthalmological and dysmorphic features. The disorder is caused by mutations in the GLB1gene (3p22.3) coding for beta-galactosidase. To date, more than 165 mutations have been identified. Deficient enzyme activity leads to toxic accumulation of gangliosides in body tissues, and particularly in the central nervous system (CNS).
The GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) drugs in development market research report provide comprehensive information on the therapeutics under development for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 15 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AceLink Therapeutics IncAllievex Corp
Azafaros BV
BioStrategies LC
Dorphan SA
Gain Therapeutics Inc
GC Biopharma Corp
IntraBio Ltd
Liberyx Therapeutics Ltd
Passage Bio Inc
Pronacera Therapeutics SL
Sanofi
Table of Contents
Table
Figures
Frequently asked questions